Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 2nd Humira Biosimilar, 1st NovoRapid Follow-On Gets Japan Listing on May 26
May 25, 2021
- MHLW Panel Backs Japan’s 1st Oncolytic Virus for Conditional Approval
May 25, 2021
- MHLW Grants Orphan Status to Eculizumab, 2 More APIs
May 25, 2021
- Japan Hails Janssen Vaccine Submission as New Option: Spokesman
May 25, 2021
- MOF Panel’s Proposal Urges More Stringent Drug Cost Control, Revisiting of Semi-Automatic Listing
May 24, 2021
- Biz Improvement Order Issued to 3 Codevelopers over Kobayashi Kako’s Fudged Data
May 24, 2021
- LDP Project Team Submits Proposal to Boost Drug Discovery Capabilities
May 24, 2021
- PMDA Review Report: Flexible Discussions Needed for Eligibility of AstraZeneca Vaccine
May 24, 2021
- PMDA Reviewing New Safety Risk for Keytruda
May 24, 2021
- Japan Approves Moderna and AstraZeneca COVID-19 Vaccines
May 21, 2021
- AstraZeneca, Moderna COVID-19 Vaccines in Line for Japan Approval on May 21
May 21, 2021
- Give AstraZeneca Shots to People Who Want, Regardless of Priority Order: Lawmakers
May 21, 2021
- Japan Govt Eyes Expedited Approval Process to Push Homegrown Vaccines
May 20, 2021
- LDP Panels Submit Proposal to PM for Commercialization of Japan-Made Vaccines
May 19, 2021
- LDP Study Group’s Draft Proposal Urges Price Maintenance for Patented Drugs
May 19, 2021
- Pharma to Govt: Maintain Prices of Patented Drugs, It’s the Global Standard
May 18, 2021
- MHLW Proposes Lifting Domestic Ban on Cannabis-Derived Drugs, Seeking “Ingredient-Based” Regulation
May 18, 2021
- Japan’s 1st Sakigake-Designated Oncolytic Virus Up for Advisory Panel Review on May 24
May 18, 2021
- AstraZeneca, Moderna COVID-19 Vaccines Up for Key Panel Review on May 20
May 17, 2021
- Japan, Pfizer Agree on 50 Million Extra Vaccine Doses by Sept-End
May 17, 2021
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…